T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function.

Immunology. 1996 Feb;87(2):198-204. Unique Identifier : AIDSLINE MED/96245971
Liang B; Ardestani S; Marchalonis JJ; Watson RR; Department of Family and Community Medicine, University of; Arizona, Tucson 85724, USA.

Abstract: C57BL/6 mice were injected with different doses of human T-cell receptor (TCR) V beta 8.1 CDR1 peptide at different times after murine retrovirus (LP-BM5) infection. Injection with TCR V beta 8.1 CDR1 peptide largely prevented the retrovirus-induced reduction in B- and T-cell proliferation, and T-helper 1 (Th1) cytokines [interleukin-2 (IL-2) and interferon-gamma (IFN-gamma)] secretion. It also suppressed T-helper 2 (Th2) cytokines (IL-6 and IL-10) production, which was stimulated by retrovirus infection. These effects were accomplished using at least 100 micrograms of peptide per mouse and the most effective dose of peptide had to be given within 4 weeks after retrovirus infection. Immunization with doses above 100 micrograms/mouse as long as 4 weeks postinfection maintained natural killer (NK) cell activity during retrovirus infection. Reducing the dose of peptide or delaying it until the disease progressed towards early murine acquired immune deficiency syndrome (AIDS) allowed development of immune dysfunction. These studies provide data suggesting that immune dysfunction, induced by murine retrovirus infection, was largely prevented by TCR V beta CDR1 peptide injection.

Keywords: Adjuvants, Immunologic Animal Body Weight Cell Culture Cytokines/BIOSYNTHESIS Cytotoxicity, Immunologic Dose-Response Relationship, Immunologic Female Immunity, Cellular *Immunization Schedule Killer Cells, Natural/IMMUNOLOGY Lymphocyte Transformation/IMMUNOLOGY Mice Mice, Inbred C57BL Murine Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL/THERAPY Receptors, Antigen, T-Cell/*IMMUNOLOGY Spleen/IMMUNOLOGY JOURNAL ARTICLE
961130
M96B1813

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .